The patent enters into force on 14 May 2025 and expires in 2041, with the possibility of extension until 2046.

“Neurodegenerative diseases cause tremendous suffering worldwide, and we continue our work to develop treatments that delay or stop disease progression. The expanded patent protection for exidavnemab through a substance patent in the EU is further evidence of our innovation capacity and ability to identify completely new ways to tackle brain diseases,” says Gunilla Osswald, CEO, BioArctic.

Related article

Global health & Local efforts: New hope in the neurodegenerative disease pipeline 

Even though many have tried and few succeeded in the quest to find viable treatments for neurodegenerative diseases, Nordic drug developers continue to take different approaches to crack the riddle.

Exidavnemab

Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as Parkinson’s disease and MSA. Exidavnemab is a monoclonal antibody (mAb) that selectively targets alpha-synuclein aggregates, such as oligomers or protofibrils. Aggregated alpha-synuclein damages the nerve cells and as exidavnemab selectively binds and eliminates these aggregates, the neuronal function and survival may be preserved, and disease progression ultimately halted.